Duvelisib is under clinical development by Secura Bio and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase II drugs for Peripheral T-Cell Lymphomas (PTCL) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Duvelisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Duvelisib (Copiktra) is an isoquinolone derivative, acts as an anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Copiktra is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma and follicular lymphoma after at least two prior therapies.
Duvelisib (IPI-145, formerly known as INK1197) is under development for the treatment of Coronavirus disease 2019 (COVID-19), melanoma, advanced relapsed and refractory hematologic cancers like chronic lymphocytic leukemia, relapsed and refractory chronic lymphocytic leukemia (second line), peripheral T-Cell lymphomas (PTCL), angioimmunoblastic T-Cell lymphoma, anaplastic large cell lymphoma, natural killer cell lymphomas, T-cell lymphomas, cutaneous T-cell lymphoma and non-hodgkin lymphomas including small lymphocytic lymphoma, follicular lymphoma, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and relapsed or refractory follicular lymphoma. It was also under development for the treatment of rheumatoid arthritis (RA), acute lymphoblastic leukemia (T-ALL or B-ALL), lymphoma, nodal, extranodal, splenic marginal zone lymphoma and diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma and allergic asthma and solid tumors including esophageal cancer, gastric cancer, colorectal cancer, head and neck cancer squamous cell carcinoma.
It is under development for the treatment of indolent non-hodgkin lymphomas including follicular lymphoma, marginal zone lymphoma (splenic, nodal, or extranodal), and SLL.
It was under development for the treatment of head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx.
Secura Bio overview
Secura Bio is a pharmaceutical company that develops innovative therapies and drugs. Its product portfolio includes COPIKTRA medicine, which is used for treating patients with Chronic Lymphocytic Leukemia (CLL) and COPIKTRA (duvelisib) a kinase inhibitor which is used to treat the patients with Relapsed or refractory CLL or SLL. The company has its operations in the US and Ireland. Secura Bio is headquartered in Las Vegas, Nevada, the US.
For a complete picture of Duvelisib’s drug-specific PTSR and LoA scores, buy the report here.